, at $35 per month. The company will also lower prices on its short-acting insulin, Apidra, by 70%.
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," Olivier Bogillot, head of U.S. General Medicines at Sanofi, said in a news release. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.
Sanofi joins both Eli Lilly and Novo Nordisk, which made similar price cut announcements earlier this month, as well as Medicare, which has begun limiting insulin costs for seniors."It seemed like only a matter of time" before Sanofi also made changes, Stacie Dusetzina, a health policy professor at Vanderbilt University Medical Center in Nashville, Tenn.
Insulin prices have been much higher in the United States than in other countries, where 8.4 million Americans rely on the medication, according to